You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Effective Covid-19 vaccine rollout unlikely before fall 2021, experts say

An effective vaccine is not likely to be available for the general public before the fall of 2021, according to experts working in the field of vaccine development

Coronavirus Vaccine | Coronavirus

Press Trust of India  |  New Delhi 

Coronavirus, vaccine, covid, drugs, Sepsivac, clinical trials
File Photo

An effective vaccine is not likely to be available for the general public before the fall of 2021, according to experts working in the field of vaccine development.

Researchers at McGill University in Canada carried out a survey of 28 experts working in vaccinology in late June 2020.

The majority of those surveyed were mostly Canadian or American academics with an average of 25 years of experience working in the field.

"Experts in our survey offered forecasts on vaccine development that were generally less optimistic than the timeline of early 2021 offered by US public officials," Jonathan Kimmelman, a professor at McGill University, said in a statement.

"In general they seem to believe that a publicly available vaccine next summer is the best-case scenario with the possibility that it may take until 2022," said Kimmelman, the senior author on the paper published in the Journal of General Internal Medicine.

Many experts also believe that there may be some false starts before an effective vaccine is available.

"The experts we surveyed believe that there is a 1 in 3 chance that the vaccine will receive a safety warning label after approval, and a 4 in 10 chance that the first large field study will not report efficacy," added Patrick Kane, the lead author of the paper, a postdoctoral fellow at McGill University.

The study also showed that about one-third of those surveyed believe that vaccine development is likely to face two main setbacks.

The first vaccine widely deployed in the US and/or Canada will receive a boxed warning from the FDA to highlight serious or life-threatening adverse reactions, the researchers said.

Also, the first large field trial in the US and/or Canada will report a null or negative result in terms of efficacy, they said.

"Our study finds that experts are largely in agreement about the timeline for a SARS-CoV-2 vaccine," said Stephen Broomell, an associate professor at Carnegie Mellon University in the US.

"While this does not track with many overly optimistic government projections, it reflects a belief that researchers are indeed on a faster pace to development compared to previous vaccines," Broomell said in a statement.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, October 02 2020. 13:55 IST